Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
br Materials and methods br
2024-06-19

Materials and methods Results Table 1 presents the metabolic phenotype of obese minipigs. After 60 d of HFHS feeding, minipigs not only showed an increased body weight (+45%), but also a perturbed SecinH3 synthesis homeostasis, with higher insulin levels (about +2-fold), HOMA-IR (+5.5-fold),
-
br Development of lorlatinib from crizotinib to a clinical
2024-06-19

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
-
br Materials and methods br
2024-06-19

Materials and methods Results Discussion Competing financial interests Acknowledgements The work was partially supported by grants from the National Natural Science Foundation of China (Grant no. 31530053 and 31401424) and National Science and Technology Support Plan (Grant no. 2013BA
-
Our previous study revealed expression
2024-06-19

Our previous study revealed expression of AhR in human parotid gland in cytoplasm of striated duct MGCD0103 sale (Drozdzik, Kowalczyk, Urasińska, & Kurzawski, 2013). In a further study we observed regulation of AhR expression and function by its specific inducer, i.e. 2,3,7,8-tetrachlorodibenzo-p-d
-
Herein we employ an adapted targeted quantitative proteomic
2024-06-19

Herein we employ an adapted targeted quantitative proteomic isotope dilution method, developed in our laboratory [[18], [19], [20], [21]], to quantify membrane transporters in fresh lung from five donors, in four immortalized human lung cell lines and in three control cell lines. We quantify twelve
-
Here we have used transcriptome analysis of primary neonatal
2024-06-19

Here, we have used transcriptome analysis of primary neonatal rat cardiomyocytes treated with either the ETR agonist endothelin-1 or the α1-AR agonist phenylephrine to assess differences in their respective signalling networks, and further probed these differences using a panel of fluorescent resona
-
Cathepsin K Activity Fluorometric Assay Kit AdipoR and Adip
2024-06-19

AdipoR1 and AdipoR2 have been reported to be present in almost all type of tissues and low Cathepsin K Activity Fluorometric Assay Kit levels have been observed in white adipose tissue (Inukai et al., 2005). These receptors have been observed to become deregulated with the onset of obesity, result
-
br Conclusions Triptans are HT B D F receptors agonists
2024-06-19

Conclusions Triptans are 5-HT1B/1D/(1F) receptors agonists and are considered as the gold standard for acute migraine treatment that have been proven effective. Unfortunately, they are contraindicated in patients with cardiovascular diseases due to their vasoconstrictor (side) effects (MaassenVan
-
Song et al reported series of triazolylsalicylamide derivati
2024-06-18

Song et al. reported series of 1,2,3-triazolylsalicylamide derivatives and screened over kinase panel and found compound 31 as most potent which inhibited Aurora-A, specifically with IC50 of 0.37 μM. Compound 31 was about 10-fold more active for Aurora-A than for Aurora-B (IC50 = 3.58 μM reported se
-
br Conflict of interest statement br
2024-06-18

Conflict of interest statement Funding Acknowledgments We thank the team at Medical and Collider-Accelerator Departments at BNL and for their support at NSRL. We thank Dr. Janice Pluth and Professor Peter O’Neill for useful discussions related to our work. Introduction The DNA damage re
-
Furthermore low affinity sites that share no structural homo
2024-06-18

Furthermore, low-affinity sites that share no structural homology with the aforementioned sites have been described in the transmembrane domain. It has been discovered that, in α1βγ2 receptors, potentiation of GABA-activated currents by high concentrations of diazepam is biphasic, with a high- and a
-
Researchers demonstrated that mitochondria are the
2024-06-18

Researchers demonstrated that mitochondria are the main producers of ROS and are the most sensitive to the effects of ROS. Mitochondria-mediated apoptosis may not be limited to the role of cytochrome c in the activation of caspase-3 and ROS may provide an alternate mitochondrial signaling pathway (H
-
br Mechanism of action In general the main targets
2024-06-18

Mechanism of action In general, the main targets for antifungal drug development are cell wall polymer (glucans, chitin, mannoproteins), cell membrane (especially ergosterol) biosynthesis, DNA and protein synthesis (topoisomerases, nucleases, elongation factors and myristoylation), and signal tr
-
br Removal of therapeutic doses of antibiotics from Marek
2024-06-18

Removal of therapeutic doses of comt inhibitors from Marek’s Disease Vaccines The impact of this change seems to vary widely among operations, probably dependent on the pre-existing quality of hatching egg production, hatchery sanitation, hatchery management, and brooding management. Increases in
-
br Polymorphic variation ERAP is polymorphic and
2024-06-18

Polymorphic variation ERAP1 is polymorphic and several single nucleotide polymorphisms (SNPs) in its gene that encode amino Bromosporine changes have been associated with predisposition to a variety of diseases, ranging from viral infections to cancer and autoimmunity (Alvarez-Navarro and Lopez
14822 records 133/989 page Previous Next First page 上5页 131132133134135 下5页 Last page